BRAF and metastatic melanoma: (102) communicated the results of a phase II trial evaluating cryopreserved autologous TIL therapy lifileucel (LN-144) in patients with metastatic melanoma in progression to anti-PD1 +/- anti-CTLA4 therapy (and BRAF/MEK inhibitors in BRAF-mutant tumors).